StreetInsider.com News Articles

Form 144 Tango Therapeutics, Inc. Filed by: NEXTECH CROSSOVER I SCSP

Wed, 17 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260617/26660657.html

Form 144 Tango Therapeutics, Inc. Filed by: NEXTECH CROSSOVER I SCSP

Wed, 17 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260617/26660657.html

Form 144 Tango Therapeutics, Inc. Filed by: Beckman Daniella

Thu, 11 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260611/26637009.html

Form 144 Tango Therapeutics, Inc. Filed by: Beckman Daniella

Thu, 11 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260611/26637009.html

Form 8-K Tango Therapeutics, Inc. For: Jun 09

Wed, 10 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260610/26630934.html

Form 8-K Tango Therapeutics, Inc. For: Jun 09

Wed, 10 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260610/26630934.html

Form 424B5 Tango Therapeutics, Inc.

Wed, 10 Jun 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260610/26630921.html

Form 424B5 Tango Therapeutics, Inc.

Wed, 10 Jun 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260610/26630921.html

Form 144 Tango Therapeutics, Inc. Filed by: Beckman Daniella

Wed, 10 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260610/26630570.html

Form 144 Tango Therapeutics, Inc. Filed by: Beckman Daniella

Wed, 10 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260610/26630570.html

Tango Therapeutics Inc. (TNGX) PT Raised to $66 at H.C. Wainwright

Wed, 10 Jun 2026 07:12:22 -0400

(Updated - June 10, 2026 7:12 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $66.00 (from $27.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Tango announced initial Phase 1 results for the combination of vopimetostat + daraxonrasib in 2L+ PDAC (n=20; 65% 2 median prior Rx; 70% liver mets) and NSCLC (n=5; 60% 2 median prior Rx; 20% liver mets). As seen in the company presentation, vopimetostat 200mg or 250mg + daraxonrasib 100mg demonstrated a 92% ORR and 100% ORR in the PDAC and NSCLC patients, respectively, and a 90%

Tango Therapeutics Inc. (TNGX) PT Raised to $66 at H.C. Wainwright

Wed, 10 Jun 2026 07:12:22 -0400

(Updated - June 10, 2026 7:12 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $66.00 (from $27.00) while maintaining a Buy rating.

Form FWP Tango Therapeutics, Inc. Filed by: Tango Therapeutics, Inc.

Wed, 10 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260610/26626093.html

Form FWP Tango Therapeutics, Inc. Filed by: Tango Therapeutics, Inc.

Wed, 10 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260610/26626093.html

Tango Therapeutics prices $600 million public offering at $30 per share

Tue, 09 Jun 2026 22:49:37 -0400

Tango Therapeutics Inc. (NASDAQ: TNGX) announced the pricing of an underwritten public offering of 18,166,667 shares of common stock and pre-funded warrants to purchase up to 1,833,395 shares at $30.00 per share. The pre-funded warrants are priced at $29.999 each, representing the share price minus the $0.001 exercise price.

The clinical-stage biotechnology company expects gross proceeds of approximately $600 million before underwriting discounts and offering expenses. The offering is scheduled to close on or around June 11, 2026, subject to standard closing conditions.